Here, we report the draft genome sequence of Bacteroides fragilis strain Z&Z143, a metronidazole-resistant bacterium isolated from a blood culture from an Ecuadorian patient hospitalized in a medical institution in Quito, Ecuador. We describe a new variant of the nim genes, which is associated with metronidazole resistance.
ABSTRACT
Here, we report the draft genome sequence of Bacteroides fragilis strain Z&Z143, a metronidazole-resistant bacterium isolated from a blood culture from an Ecuadorian patient hospitalized in a medical institution in Quito, Ecuador. We describe a new variant of the nim genes, which is associated with metronidazole resistance.
ANNOUNCEMENT
Bacteroides fragilis is a predominant organism in the colon microbiota (1). It is one of the most frequently isolated species from clinical infections and bacteremia (2). The most common antimicrobial drug for the treatment of B. fragilis infections is metronidazole (3). Worldwide, the prevalence of metronidazole-resistant B. fragilis has been reported to be between 0.5% and 7.8% (4). The resistance is often conferred by the nim genes, which encode 5-nitroimidazole reductase (5). Before this analysis, 11 variants of the nim gene (nimA to nimK) had been identified, mainly in Bacteroides spp. and rarely in other anaerobes (6).
B. fragilis was isolated from a blood culture from a patient who had abdominal surgery and was hospitalized in Quito, Ecuador. It was obtained using a Bactec lytic anaerobic blood culture bottle (Becton, Dickinson, USA) after routine subculture on a BBL Bacteroides bile esculin (BBE) agar plate (Becton, Dickinson) at 37°C in an anaerobic atmosphere for 24 h. The API 20A system (bioMérieux, Marcy l’Étoile, France) was applied for the identification of B. fragilis (Z&Z143). MICs were determined using a Sensititre anaerobe MIC ANO2B plate (Thermo Fisher Scientific, USA). The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines (7). Total DNA from the B. fragilis Z&Z143 strain, harvested from BBE agar, was extracted using the High Pure PCR template preparation kit (Roche Diagnostics, Switzerland), according to the manufacturer’s instructions. The TruSeq Nano DNA library preparation kit (Illumina) was used to prepare libraries that were sequenced using the Illumina HiSeq system in 100-bp paired-end runs, producing a total of 10,317,898 reads. The Trimmomatic version 0.39 tool was used to trim and filter low-quality reads. Assembly was conducted with Velvet 1.2 (https://cge.cbs.dtu.dk/services/Assembler/) (8), resulting in 75 contigs >200 bp in size and an estimated genome size of 5 Mb. Antimicrobial resistance genes were determined using ResFinder (9). Default parameters were used for all software.
The isolated B. fragilis strain was characterized according to its phenotypic and genotyping resistance (Table 1).
TABLE 1.
Phenotypic and genotypic antimicrobial susceptibility profile
| Antimicrobial | MIC breakpoint (mg/liter) | Resistance interpretive categorya | Resistance gene |
|---|---|---|---|
| Ampicillin-sulbactam | 16/8 | R | cepA |
| Amoxicillin-clavulanic acid | 4/2 | S | |
| Cefotetan Na | ≤4 | S | |
| Penicillin | ≥4 | R | |
| Imipenem | ≤0.12 | S | |
| Meropenem | ≤0.5 | S | |
| Clindamycin | ≥8 | R | ermF |
| Cefoxitin | 4 | S | |
| Metronidazole | ≥16 | R | nimL |
| Chloramphenicol | ≥64 | R | Chloramphenicol-acetyltransferase |
| Ampicillin | ≥16 | R | |
| Piperacillin | 128 | R | |
| Tetracycline | ≥8 | R | tetQ |
| Mezlocillin | 128 | NA | |
| Piperacillin-tazobactam | 2/4 | S |
The results were interpreted using CLSI M100, 29th ed. (7). R, resistant; S, susceptible; NA, CLSI breakpoints were not available.
The draft genome of metronidazole-resistant B. fragilis Z&Z143 has a length of 5,158,698 bp, with an N50 value of 196,742 bp, genome coverage of 200.0×, and G+C content of 43.1%. A total of 4,320 protein-coding genes and 71 RNA-coding sequences were detected after manual inspection of the annotations using the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) (https://www.ncbi.nlm.nih.gov/genome/annotation_prok/) (10).
Functional annotation with the PGAP highlighted genes that were associated with the nitroimidazole reductase protein, which is responsible for the metronidazole resistance in this strain. A BLAST search of the Z&Z143 nitroimidazole resistance gene resulted in a nucleic acid identity of 89% with the nimC gene of Bacteroides thetaiotaomicron (GenBank accession number NG_048013) and 83% with the nimF gene of Bacteroides vulgatus (GenBank accession number AJ515145). The presence of this nim gene in B. fragilis was further confirmed by PCR using the NIM-3 and NIM-5 primers (11). The new variant of the nim gene conferring metronidazole resistance described in this study was named nimL (GenBank accession number MK251988).
The increasing diversity of nim gene variants is of great concern because there is a possibility for new emerging multidrug-resistant Bacteroides strains. Furthermore, the activity of metronidazole, traditionally used as an empirical therapy for anaerobic infections, might be compromised.
Data availability.
The genome sequence was deposited under GenBank accession number SRKB00000000, BioProject number PRJNA530267, SRA accession number SRR10193381, and BioSample accession number SAMN11310039.
ACKNOWLEDGMENT
This study was supported by grant MIC014 from the Unidad de Investigaciones en Biomedicina from Zurita & Zurita Laboratorios.
REFERENCES
- 1.Aldridge KE, Sanders CV. 2002. Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole. Anaerobe 8:301–305. doi: 10.1016/S1075-9964(03)00028-3. [DOI] [PubMed] [Google Scholar]
- 2.Wexler HM. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20:593–621. doi: 10.1128/CMR.00008-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Löfmark S, Edlund C, Nord CE. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 1:S16–S23. doi: 10.1086/647939. [DOI] [PubMed] [Google Scholar]
- 4.Ghotaslou R, Bannazadeh Baghi H, Alizadeh N, Yekani M, Arbabi S, Memar MY. 2018. Mechanisms of Bacteroides fragilis resistance to metronidazole. Infect Genet Evol 64:156–163. doi: 10.1016/j.meegid.2018.06.020. [DOI] [PubMed] [Google Scholar]
- 5.Carlier JP, Sellier N, Rager MN, Reysset G. 1997. Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Antimicrob Agents Chemother 41:1495–1499. doi: 10.1128/AAC.41.7.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Alauzet C, Lozniewski A, Marchandin H. 2019. Metronidazole resistance and nim genes in anaerobes: a review. Anaerobe 55:40–53. doi: 10.1016/j.anaerobe.2018.10.004. [DOI] [PubMed] [Google Scholar]
- 7.CLSI. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100. CLSI, Wayne, PA. [Google Scholar]
- 8.Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol 50:1355–1361. doi: 10.1128/JCM.06094-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 67:2640–2644. doi: 10.1093/jac/dks261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tatusova T, Dicuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res 44:6614. doi: 10.1093/nar/gkw569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Trinh S, Reysset G. 1996. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J Clin Microbiol 34:2078–2084. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The genome sequence was deposited under GenBank accession number SRKB00000000, BioProject number PRJNA530267, SRA accession number SRR10193381, and BioSample accession number SAMN11310039.